Xeris Pharmaceuticals Ownership
| XERS Stock | USD 4.82 0.26 5.70% |
Shares in Circulation | First Issued 2016-12-31 | Previous Quarter 149 M | Current Value 149.1 M | Avarage Shares Outstanding 70.7 M | Quarterly Volatility 58.4 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Xeris |
Xeris Stock Ownership Analysis
About 43.0% of the company outstanding shares are owned by institutional investors. The company recorded a loss per share of 0.37. Xeris Pharmaceuticals had not issued any dividends in recent years. The entity had 1:1 split on the 6th of October 2021. Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. Xeris Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 294 people. For more information please call Paul Edick at 844 445 5704 or visit https://www.xerispharma.com.Besides selling stocks to institutional investors, Xeris Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Xeris Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Xeris Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Xeris Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Xeris Pharmaceuticals Insider Trades History
Roughly 4.0% of Xeris Pharmaceuticals are currently held by insiders. Unlike Xeris Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Xeris Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Xeris Pharmaceuticals' insider trades
Xeris Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Xeris Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Xeris Pharmaceuticals backward and forwards among themselves. Xeris Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Xeris Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2024-12-31 | 1.7 M | Goldman Sachs Group Inc | 2024-12-31 | 1.6 M | D. E. Shaw & Co Lp | 2024-12-31 | 1.4 M | Northern Trust Corp | 2024-12-31 | 1.2 M | Jpmorgan Chase & Co | 2024-12-31 | 1 M | Bank Of America Corp | 2024-12-31 | 991.7 K | Aqr Capital Management Llc | 2024-12-31 | 834.9 K | Citadel Advisors Llc | 2024-12-31 | 833.3 K | Centerbook Partners Lp | 2024-12-31 | 690.1 K | Blackrock Inc | 2024-12-31 | 10.8 M | Vanguard Group Inc | 2024-12-31 | 7.9 M |
Xeris Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Xeris Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Xeris Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Xeris Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Xeris Pharmaceuticals Outstanding Bonds
Xeris Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Xeris Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Xeris bonds can be classified according to their maturity, which is the date when Xeris Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| XEROX HLDGS P Corp BondUS98421MAB28 | View | |
| XEROX HLDGS P Corp BondUS98421MAA45 | View | |
| US98420EAB11 Corp BondUS98420EAB11 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Xeris Pharmaceuticals Corporate Filings
F3 | 7th of March 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 6th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 3rd of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Xeris Stock Analysis
When running Xeris Pharmaceuticals' price analysis, check to measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.